INVO Bioscience Inc (INVO)

[Cburg]

http://www.invobioscience.com/pdf/Shareholder%20update%20Mar%202016.pdf

March 28, 2016
Dear INVO Bioscience shareholders and friends,
We would like to thank all of you true believers who have continued to support us as shareholders. We are
confident all of our hard work and perseverance will pay off for all of us in the future.
Since receiving FDA clearance at the end of last year, the INVO team has been very busy, working diligently to get
physicians trained and prepared to offer the INVO procedure. With our small staff, we have trained a number of
physician groups across the U.S., specifically in the West and Southwest. Now familiarized, these physician groups
are prepared and will plan to begin offering INVO cycles in the coming months. We will continue to educate more
physicians on the INVO procedure in the second quarter working with other interested physicians and potential
customers to launch the INVOcell product and procedure here in the United States. We anticipate being able to
announce more centers adopting and offering the INVO in the near future.
As many of you saw, we were excited to announce we launched INVO at IVF Phoenix in Scottsdale and Mesa
Arizona over the past week. We are very enthusiastic about their plans to treat patients that previously could not
obtain fertility treatment due to the cost of traditional IVF. This is the first step in INVO becoming the standard of
care. This implementation process requires not only INVO resources but also the resources of the physicians. It
takes time and effort by the physician(s) and their entire office staff.
In November 2015, INVO engaged a team of master level interns from University of Texas-Austin in a marketing
project that provided us with some critical market information to kick start a launch. In December, we asked more
master level interns from a Boston University program to join our team for the spring semester. The interns have
been assisting with a number of activities such as: building a contact database, implementing a marketing
campaign, assisting with the re-design of our website and product brochures, an infertility survey, creating an
animated information video, and some engineering initiatives around new product development activities. This
additional staff is helping to get needed tasks done without incurring the costs of additional employees.
In our last update, we stated that INVO was actively formulating plans to secure proper funding. This funding will
allow the Company the ability to move forward in the right direction starting with becoming current with our SEC
reporting. We completed a small round of funding to allow us to take this step. During recent discussions with the
SEC, we learned they will require INVO to file all of our past Annual Reports on Form 10K as well as the quarterly
financial information for the last five outstanding years. This is a time consuming and complicated process since
the audit not only requires all the financial information to be up to date but also all of the supporting
documentation to be provided. Currently, we are working diligently to achieve this. After discussions with our
auditing firm, due to the work required for the audit, originally scheduled for the end of the first quarter of 2016
(March 31, 2016) our goal now is to become current with filings in June 2016.

This SEC filing and ongoing compliance is needed and required to secure the necessary long term financing for
appropriate execution of a full U.S. launch, which includes adding required personnel enabling INVO Bioscience to
grow and become a world leader in the reproductive medicine and infertility market.
At this point, we would like to draw a reference of INVO Bioscience to our industry of reproductive medicine. Up
until November, we were in the pregnancy stage with all of the difficulties that can go along with it. We have been
struggling with limited resources but continued to move forward looking at the end result. Then on November 2,
2015 it happened, FDA delivered the wonderful news, clearance granted and INVO was born in the U.S. Now in
our infancy, we have a ways to go. We are doing the basic things that need to be done to help this baby develop into
a healthy child. Our view is not about the past and what we have endured but what the future brings and as
shareholders we trust you feel the same.
We continue to get questions about the financial status of the company. We are disappointed we are not filing our
multi-year 10K at this point and we know you have been waiting for this information. We have stated all along our
revenues are minimal. In addition, we stripped all of our expenses down to the necessary items related to the FDA
clearance, maintaining our patents and shipping to our existing doctors who requested INVOcells. With that stated,
we incurred losses. To specifically answer one of the questions, you have been asking, our approximate revenues
have been:
2010 2011 2012 2013 2014 2015
Revenues $67,000 $71,000 $57,000 $29,000 $19,000 $9,000
We say approximate because these numbers have not been audited and they could change. Due to our limited
funds we were unable to be in countries driving outside U.S. sales and marketing efforts. Our funds were devoted
to FDA clearance and our approach was successful. Not that it is indicative of what 2016 will be, but our Q1
revenues to date exceed what we sold in all of 2015.
As mentioned above, we are in discussions to secure proper financing. At this point, we continue to have limited
funding and can only address the items we must to move forward. The next round of funding is essential to
execute our business plan which is focused on marketing and product launch. We will inform you all again upon
securing that financing.
Another question that we may answer has been how many shares are outstanding: Earlier this month we filed our
Massachusetts Annual Report and indicated we have 137,086,000 shares outstanding.
Many activities are taking place in order to launch INVO procedures across the United States, manufacturing of
additional product and accessories, preparing for the yearly re-audit of our ISO certification and of course initiating
a full product launch through our marketing campaign to physicians and industry leaders. This process will take
some time but obtaining financing and additional human resources will enable us to move forward at a quicker
pace in the near future. We appreciate your understanding, continued support and patience as this process of
expanding the current market occurs. We continue to progress forward in our mission to expand fertility treatment
options across the US and the globe.
Again thank you to those shareholders who continue to support INVO in this journey. We hope to make significant
progress in the coming months and look forward to great success in 2016.
The INVO Team,
Katie Claude
Kathleen Karloff, CEO Claude Ranoux, President
Private Securities Litigation Reform Act of1995
This letter to the shareholders includes forward-looking statements within the meaning of Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of
the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of
operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities,
plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if,"
"believe," "plan,""estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forwardlooking
statements. All forward- looking statements involve risks, uncertainties and contingencies, many of which are beyond
our control, which may cause actual results, performance, or achievements to differ materially from anticipated results,
performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking
statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such
obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or
otherwise